Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Activated B-cell Type
• Diffuse Large B-cell Lymphoma Germinal Center B-cell Type
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• T-cell Histiocyte-rich Large B-cell Lymphoma

Drugs mentioned

• TAK-659 (TAK-659)

Snippet

Sponsor: Northwestern University | Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 1 | Status: COMPLETED | Results posted: 2025-01-29